source
- Roivant’s inhaled pulmonary hypertension drug mosliciguat shows strong Phase 2 resultsRoivant invested $14 million in Bayer's inhaled soluble guanylate cyclase activator mosliciguat after a $294 million biobucks agreement in 2024, and promptly advanced the candidate into a Phase 2 s…
- Novartis pauses CAR-T trials after three patient deathsNovartis announced a pause on its experimental CAR-T therapy after three patients died while receiving the treatment. The company said it will halt ongoing immunology and neuroscience studies relat…